T and B Lymphocytes in Breast Cancer

Teasdale, C.; Thatcher, J.; Whitehead, Robert H.; Chare, M. J. B.; Hughes, L. E.

doi:10.1016/s0140-6736(77)91401-5

Cited by 13 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, not all studies showed a difference of lymphocyte counts with different stages of breast cancer, [36,38] nor that higher lymphocyte count always correlated with better prognosis. In women with breast cancer and proven metastases to 1-3 axillary nodes, Meyer [29] noted that patients with preoperative lymphocyte count greater than 2,000 per m3 actually had higher rate of 5-year relapse.…”

Section: Discussionmentioning

confidence: 90%

“…They noted that patients with TNM stage 111 lesions had higher lymphocyte count than those with stage I, 11, or IV disease. Study of T or B subpopulations of lymphocyte in patients with various stages of breast carcinoma also showed no consistent changes [24,28,36,37,39,40,42].…”

Section: Discussionmentioning

confidence: 95%

“…This finding is hard to explain. However, Teasdale et a1 [36] also noted that not all patients with breast cancer had depressed number of peripheral lymphocyte count. They noted that patients with TNM stage 111 lesions had higher lymphocyte count than those with stage I, 11, or IV disease.…”

Section: Discussionmentioning

confidence: 97%

See 2 more Smart Citations

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Lee

1984

Journal of Surgical Oncology

View full text Add to dashboard Cite

General immunocompetence was examined in 125 patients with various stages of breast cancer. Tests include peripheral blood lymphocyte count, serum protein electrophoresis, quantitative immunoglobulins, CEA level, and delayed cutaneous hypersensitivity (DCH) reaction to six recall antigens (PPD, Monilia, mumps, Varidase, histoplasmin, and coccidioidin). About one third of the patients responded positively to each of the first four antigens, whereas 12% reacted to histoplasmin and 4% to coccidioidin. In this study, DCH to recall antigens had no prognostic value because the distributions of skin test reactivity were similar among patients with different stages of breast carcinoma. And among patients with similar stage of disease the relapse rates were similar for those who reacted and those who were anergic. But peripheral lymphocyte count had definite prognostic value because patients with advanced stage (group III/IV) and those who were anergic had significantly lower lymphocyte counts. Among patients with relatively early stages of breast carcinoma (group I/II), those who had higher lymphocyte count (greater than or equal to 2,000/mm3) had lower chance of having relapse up to 5 years after mastectomy.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Lee

1984

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…These findings are hard to explain. However, Teasdale et al (27) also noted that not all patients with breast cancer had a depressed peripheral lymphocyte count. They noted that pa-tients with TNM stage III lesions had higher lymphocyte counts than those with stage I, II or IV disease.…”

Section: Year Year Yearmentioning

confidence: 99%

Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis

Lee

Sheikh

Quismorio

et al. 1985

Breast Cancer Res Tr

View full text Add to dashboard Cite

Serum antibodies to breast tumor antigen(s) and circulating autoantibodies were tested in 175 patients with various stages of carcinoma of the breast, followed for a mean period of 51 months. Antibodies to surface membrane and to cytoplasmic antigens of autologous and allogeneic tumor cells were measured. Peripheral lymphocyte count and skin reaction to six recall antigens were also tested. Patients with metastatic disease had significantly lower prevalence of antibodies to autologous tumor cells and lower total lymphocyte count than patients with early breast cancer. Patients with locally advanced disease (greater than or equal to 4 positive axillary nodes) had the highest frequency of anti-tumor antibodies, the second highest lymphocyte count, but with the lowest prevalance of autoantibodies. Presence or absence of anti-tumor or autoantibody did not correlate with results of skin tests or other standard blood tests. Among patients with locally advanced or metastatic breast cancer, those who had a positive skin test or whose lymphocyte count was 1500 to 2500 per cu mm had significantly better 5-year absolute survival rates (p = 0.04, p = 0.002, respectively). This study suggests that in patients with locally advanced or metastatic breast cancers, skin test reactivity and optimal peripheral lymphocyte count may be useful prognostic indicators. In contrast, neither the presence of anti-tumor antibodies to membrane or cytoplasmic antigens, nor the presence of autoantibodies, correlates with prognosis in patients with early or late breast cancers.

show abstract

Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients

Heidenreich

Jagla

Schussler

et al. 1979

Cancer

View full text Add to dashboard Cite

Mononuclear cells from peripheral blood and draining lymph nodes of 40 patients with invasive locoregional breast cancer were examined for immunological cell surface markers (E, EAhuman, EAox, EAC, SIg pos.). Concomitantly, blood lymphocytes from 36 healthy women and axillary and mesenteric lymph-nodes from patients without malignant diseases were tested as controls. In peripheral blood of tumor patients E rosette-forming cells were slightly diminished as compared to the control group, whereas EAox and EAC rosette-forming cells were increased. These differences may be age-dependent rather than tumor-related. In the draining lymph nodes of breast cancer patients as well as in the control lymph nodes, the percentages of EAC rosette-forming cells and SIg positive lymphocytes were significantly increased compared to peripheral blood, whereas E and EAhuman rosette values remained unchanged. Percentages of EAox rosettes on the other hand were strongly diminished in the draining lymph nodes, suggesting that the EAhuman and EAox rosetting techniques detect 2 types of Fc-receptor bearing cells. No significant differences were found between the cell surface marker analysis of tumor-free and metastatic lymph nodes of breast cancer patients and the control lymph nodes.

show abstract

T and B Lymphocytes in Breast Cancer

Cited by 13 publications

References 6 publications

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Delayed cutaneous hypersensitivity, lymphocyte count, and blood tests in patients with breast carcinoma

Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis

Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients

Contact Info

Product

Resources

About